Since its identification, PCAT6 has been suggested to be oncogenic and promote tumor progression via different mechanisms in various carcinomas (Figure 1), including lung cancer, GC, colorectal cancer (CRC), hepatocellular carcinoma (HCC), bladder cancer (BC), breast cancer, cervical cancer (CC), and osteosarcoma. Here, PCAT6 is linked to breast cancer.